Clinical Data Where Variability is More Important than Averages
In clinical studies, efficacies of new treatments are usually assessed by comparing averages of new treatment results versus control or placebo. However, averages do not tell the whole story, and the spread of the data may be more relevant. E.g., when we assess how a drug reaches various organs, variability of drug concentrations is important, as in some cases too little and in other cases dangerously high levels get through. Also, for the assessment of the pharmacological response to a drug, variabilities may be important. E.g., the effects on circadian glucose levels in patients with diabetes mellitus of a slow-release-insulin and acute-release-insulin formula are different. The latter formula is likely to produce more low and high glucose levels than the former formula. Spread or variability of the data is a determinant of diabetic control, and predictor of hypoglycaemic / hyperglycemic events. As an example, in a parallel-group study of n = 200 the former and latter formulas produced mean glucoses of 7.9 and 7.1 mmol/l, while standard deviations were 4.2 and 8.4 mmol/l respectively. This suggests that, although the slow-release formula did not produce a better mean glucose level, it did produce a smaller spread in the data. How do we test these kinds of data. Clinical investigators, although they are generally familiar with testing differences between averages, have difficulties testing differences between variabilities. The current chapter gives examples of situations where variability is more relevant than averages. It also gives simple statistical methods for testing such data. Statistical tests comparing mean values instead of variabilities are relatively simple and are one method everyone seems to learn. It is a service to the readership of this book to put more emphasis on variability.
KeywordsPlacebo Pneumonia Bacillus Caffeine Pseudomonas
Unable to display preview. Download preview PDF.
- 1.Chambers HF, Sande MA. Antimicrobial agents: the aminoglycosides. In Goodman and Gillman's Pharmacological basis of therapeutics, 9th edition, McGraw Hill, New York, USA, 1996; pp 1103–21Google Scholar
- 2.Cleophas TJ, Van der Meulen J, Zwinderman AH. Nighttime hypotension in hypertensive patients prevented by beta-blockers but not by angiotensin converting enzyme inhibitors or calcium channel blockers. Eur J Intern Med 1998; 9: 251–7.Google Scholar
- 5.Tothfalusi L, Endrenyl L. Evaluation of some properties of individual bioequivalence from replicate-design studies. Int J Clin Pharmacol Ther 2001; 39: 162–6.Google Scholar
- 7.Petrie A, Sabin C. Medical statistics at a glance. London, UK, Blackwell Science Ltd, 2000.Google Scholar
- 11.Kendall MG, Stuart A. Rank correlation methods. 3rd edition, London, UK, Griffin, 1963.Google Scholar
- 12.Siegel S. Non-parametric methods for behavioural sciences. New York, McGraw Hill, 1956.Google Scholar